Charles Keller, M.D.
Charles Keller, M.D. childhood cancer physician-scientist and NIH R01- funded investigator specializing in the development of more effective, less toxic therapies for the pediatric muscle cancer, rhabdomyosarcoma, and the pediatric cancer brain tumor, medulloblastoma. His special interest is advanced disease spreading beyond the initial location of the cancer. Dr. Keller is investigating whether the genes thought to be responsible for the initial tumors are also vital when the disease progresses, thereby indentifying targets for new medical therapies.
In June 2010, Dr. Keller joined the Pape’ Family Pediatric Research Institute, Department of Pediatrics, Oregon Health and Science University as an Associate Professor and Leader of the Pediatric Cancer Biology Program. He also directs the Pediatric Preclinical Testing Initiative, which is an NCI-affiliated childhood cancer drug-testing program. Dr. Keller is co-chair of the brain tumor developmental therapeutics committee (CNS- DVL) of the Children’s Oncology Group (COG), and is a member of the soft tissue sarcoma (STS) committee of the COG. Prior to attending Baylor College of Medicine where he received his M.D. degree, Dr. Keller attended Tulane University where he received a degree in Biomedical Engineering. He has completed his internship and residency in Pediatrics at Texas Children’s Hospital, and trained in Pediatric Hematology- Oncology at the University of Utah.
Stefano Cairo, Ph.D.
Stefano Cairo, Ph.D. received his Ph.D. in human genetics in 2004 form Telethon Institute of Genetics and Medicine (TIGEM) in Naples, Italy. After receiving his Ph.D., Dr. Cairo trained in the laboratory of Dr. Marie Annick Buendia at Institut Pasteur (Paris, France) where he studied liver disease and cancer, specifically hepatoblastoma. Dr. Cairo has published several high-impact, sentinel scientific papers leading to new insights into what causes and drives hepatoblastoma.
In December 2009, Dr. Cairo joined Xentech in Paris, France, a cancer research institute where preclinical studies are conducted in hopes of oncology drug development. At Xentech, Dr. Cairo leads studies of pediatric and adult tumor models to identify genetic markers, pathways and signatures possibly predicting tumor response to conventional and/or innovative anti-cancer treatments.
Early County High School, Blakely, Ga.
The Beta Club at Early County High School in Blakely, Ga., partnered with our foundation in the fight against cancer! The Beta Club raised $2,000 for the foundation through its 2012 Coca-Cola® fundraiser! Each year the club chooses an organization to support, and we are extremely blessed and thankful they chose the Macy Easom Cancer Research. Thank you Beta Club!